EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors

Yunpeng Yang, Tyler Mandt, David Mittelstein, Manasi Das, Panyisha Wu, Mansur A Ghani, Ritvik Illindala, Nicole F Steinmetz, Adam M Burgoyne, Zachary Berman, Nicholas Webster, Isabel G Newton

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-025-04286-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Yunpeng Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Division of Interventional Radiology, University of California San Diego, San Diego, CA, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Toll-Like Receptor 9, Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Society of Interventional Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rising incidence of hepatocellular carcinoma (HCC) is partly driven by metabolic dysfunction-associated steatohepatitis (MASH). Recurrence after treatment is high, and advanced disease carries a poor prognosis. The immunosuppressive tumor microenvironment (TME) in HCC limits the efficacy of immunotherapy, necessitating innovative approaches. To evaluate the efficacy of a novel therapeutic strategy designed to stimulate an antitumor immune response by combining cryoablation (Cryo) to release tumor antigen with an intratumoral immunostimulant (CpG) to facilitate immune recognition and dual immune checkpoint inhibitors (CPI) to disinhibit T cells. RIL-175 cells were orthotopically injected into two liver lobes in mice on a MASH-inducing diet. One tumor in each mouse was treated with partial Cryo, systemic dual CPI (anti-PD-1 and anti-CTLA-4), intratumoral TLR9 agonist CpG, or combinations thereof, while the second tumor was untreated. Tumor growth was monitored prior to and after ablation. Immune cell profiles and cytokine levels in both treated and untreated tumors were analyzed postmortem. The combined treatment of Cryo with CpG and dual CPI achieved the strongest tumor control and survival benefit. Cryo alone increased growth of the untreated tumor but addition of CpG and CPI reversed this effect. Immunologically, CPI primarily drove CTL expansion and PD-1 modulation, whereas CpG suppressed Tregs. Cryo monotherapy leads to immunosuppression, characterized by elevated Tregs, MDSCs, and PD-1 expression. Combining Cryo with CpG and CPI counteracts the inherent limitations of each therapy and enhances systemic anti-tumor immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsToll-Like Receptor 9Immune Checkpoint InhibitorsToll-Like Receptor AgonistsAnimalsMiceMice, Inbred C57BLCryosurgeryTumor MicroenvironmentCombined Modality TherapyImmunotherapyCpG IslandsDisease ProgressionLymphocyte ActivationT-Lymphocytes, CytotoxicT-Lymphocytes, Helper-InducerProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

AbscopalCpGCryotherapyDual checkpoint blockadeHepatocellular carcinoma

Substanzen

Toll-Like Receptor 9Tlr9 protein, mouseImmune Checkpoint InhibitorsToll-Like Receptor AgonistsPdcd1 protein, mouseProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Radiology, Division of Interventional Radiology, University of California San Diego, San Diego, CA, USA.
  • VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA, 92161, USA.
  • Department of Medicine, University of California San Diego, La Jolla, CA, USA.
  • School of Medicine, University of California San Diego, La Jolla, CA, USA.
  • Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  • Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, USA.

Förderung

  • Society of Interventional Oncology

Zitieren

APA

Yang, Y., Mandt, T., Mittelstein, D., Das, M., Wu, P., Ghani, M. A., Illindala, R., Steinmetz, N. F., Burgoyne, A. M., Berman, Z., Webster, N., & Newton, I. G. (2026). Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04286-8

Vancouver

Yang Y, Mandt T, Mittelstein D, Das M, Wu P, Ghani MA, et al. Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-025-04286-8

BibTeX
@article{Yang2026,
  author = {Yang, Yunpeng and Mandt, Tyler and Mittelstein, David and Das, Manasi and Wu, Panyisha and Ghani, Mansur A and Illindala, Ritvik and Steinmetz, Nicole F and Burgoyne, Adam M and Berman, Zachary and Webster, Nicholas and Newton, Isabel G},
  title = {Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-025-04286-8}
}
Kostenlos starten →